Loading
institutionsInstitution
Radboudumc Centre for Oncology
The university hospital of Nijmegen, a leading Dutch centre for prostate imaging, dendritic cell vaccines and tumour immunology, currently in OECI accreditation.
Also called: Radboud University Medical Center
Overview
Radboud University Medical Center is the academic hospital of Radboud University and a tertiary cancer centre for the east of the Netherlands. Its Centre for Oncology integrates medical oncology, radiotherapy, haematology, surgical oncology and urology, and its research is internationally recognised in prostate MRI and PSMA imaging, dendritic cell vaccination and tumour immunology (Radboud Institute for Molecular Life Sciences), hereditary cancer, and hepatobiliary and pancreatic surgery. Radboudumc is listed by the Organisation of European Cancer Institutes as in accreditation.
Location
Nijmegen, NL
Type
hospital · Radboud University
Website
Newsweek 2026 oncology rank
Not in top 300 listing used
OnCo score
#384 · 16 points (0 Newsweek + 0 NCI + 16 from 8 linked objects) · ranking
Research output
From OpenAlex, oncology works in the last five years (2022 to 2026, current year in progress); counted on 2026-09-16.
Matched to Radboud University Medical Center, including child institutions. 1,163 works · 11,871 citations · 86% open access · 11% clinical trials · 3% reviews.
Oncology works per year
2622022
2512023
2242024
2672025
1592026
Most works
- Marc G. Besselink112 works
- Martijn W.J. Stommel98 works
- Bas Groot Koerkamp88 works
- Ignace H. J. T. de Hingh81 works
- Irıs D. Nagtegaal77 works
- Johannes H.W. de Wilt70 works
- Hjalmar C. van Santvoort65 works
- Vincent E. de Meijer58 works
- Olivier R. Busch56 works
- Bert A. Bonsing55 works
Most cited
- Prostate imaging and PSMA
- Dendritic cell vaccines
- Tumour immunology
- Hereditary cancer
Bertine Lahuis
Chair of the Executive Board (voorzitter Raad van Bestuur), Radboudumc, Nijmegen
Hospital governanceAcademic medicinePsychiatry
Chair of the executive board of Radboud university medical centre in Nijmegen, the academic hospital that houses the Radboudumc Centre for Oncology.
Haiko Bloemendal
Representative of Radboudumc Centre for Oncology to the Organisation of European Cancer Institutes
Cancer centre representation (OECI)
Haiko Bloemendal represents Radboudumc Centre for Oncology in the Organisation of European Cancer Institutes, which lists the centre among its members in The Netherlands.
reviewGastroenterology 2019276 citations
Terminology, molecular features, epidemiology, and management of serrated colorectal neoplasia
It links the molecular route to the practical failure mode: interval cancers after a clear colonoscopy are disproportionately serrated, so detection quality is a molecular problem as much as a technical one.
meta analysisClinical Cancer Research 2014604 citations
Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies
It fixes the metastatic prevalence figures every subsequent trial design has used, and it separates two biomarkers that travel together: BRAF, not mismatch repair deficiency, is what makes the prognosis bad.
observationalBritish Journal of Cancer 2009395 citations
Deficient mismatch repair system in patients with sporadic advanced colorectal cancer
It is the reason the immunotherapy-eligible fraction of metastatic colorectal cancer is about 5% rather than the 15% quoted for resected disease, and it frames microsatellite instability as a barrier to metastasis that becomes a liability once crossed.
basicNature Genetics 2009changed practice581 citations
Heritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1
EPCAM deletion testing is now part of Lynch syndrome panels, and it explains the MSH2-deficient tumours in families where sequencing of the four repair genes comes back clean.
Similar pages
- PersonRosaline den Blanken
Shares Rijnstate, Organisation of European Cancer Institutes.
- TermMicrosatellite-stable (MSS) / mismatch-repair proficient (pMMR)
Shares Deficient mismatch repair system in patients with sporadic advanced colorectal cancer, Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studies.
- TrialPSMA PET Combined With MRI for the Detection of PCa
Shares PSMA PET, Prostate cancer.
- CompanyLightpoint Medical
Shares PSMA PET, Prostate cancer.
- PersonJeremie Calais
Shares PSMA PET, Prostate cancer.
- InstitutionTurku University Hospital Cancer Centre
Shares PSMA PET, Organisation of European Cancer Institutes.
- IdeaQualify PSMA PET tumour volume as a validated imaging biomarker
Shares PSMA PET, Prostate cancer.
- TrialPOP-RT
Shares PSMA PET, Prostate cancer.
cancers
technologies
institutions
people
key papers
Deficient mismatch repair system in patients with sporadic advanced colorectal cancerHeritable somatic methylation and inactivation of MSH2 in families with Lynch syndrome due to deletion of the 3' exons of TACSTD1Mismatch repair status and BRAF mutation status in metastatic colorectal cancer: a pooled analysis of the CAIRO, CAIRO2, COIN and FOCUS studiesTerminology, molecular features, epidemiology, and management of serrated colorectal neoplasia
Open-source projects
All open source in oncology →Open-source projects that this organisation maintains, from OnCo's own catalogue: licence and last activity as the repository reported them on the day of the fetch. Listing is not endorsement; check the licence before reuse and the validation before clinical use.
Radboud's Automated Slide Analysis Platform for viewing and annotating whole-slide images.
Preprocessing from the PI-CAI challenge for AI detection of clinically significant prostate cancer on biparametric MRI.